HF Advisory Group LLC Buys 7,548 Shares of Amgen Inc. $AMGN

HF Advisory Group LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 341.8% during the fourth quarter, Holdings Channel reports. The firm owned 9,756 shares of the medical research company’s stock after purchasing an additional 7,548 shares during the period. HF Advisory Group LLC’s holdings in Amgen were worth $3,193,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of AMGN. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the fourth quarter valued at approximately $26,000. Howard Hughes Medical Institute purchased a new stake in Amgen in the 2nd quarter valued at $32,000. Olistico Wealth LLC bought a new position in Amgen during the 4th quarter valued at $33,000. Cloud Capital Management LLC bought a new position in Amgen during the 3rd quarter valued at $34,000. Finally, Saranac Partners Ltd purchased a new position in Amgen during the 3rd quarter worth $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.4%

NASDAQ AMGN opened at $353.28 on Thursday. The business’s fifty day moving average is $363.57 and its 200-day moving average is $331.74. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock has a market capitalization of $190.44 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 3.49 and a beta of 0.47. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the business earned $5.31 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst/sector endorsements: recent analyst commentary (Zacks) highlights Amgen’s strong drug portfolio and resilience versus sector headwinds, which supports investor sentiment and helps the stock. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Positive Sentiment: Inclusion in buy lists: Amgen appears in a recent “5 Best Pharma Stocks to Invest In Now” roundup, which can attract longer‑term inflows and positive sentiment from retail/institutional investors. 5 Best Pharma Stocks to Invest In Now
• Neutral Sentiment: Brokerage consensus: a recent survey shows AMGN carries an average “Hold” rating from brokerages — not a downgrade but a sign analysts see limited near‑term upside absent new catalysts. Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages
• Negative Sentiment: Safety alert on Tavneos: the U.S. FDA has flagged multiple cases of drug‑induced liver injury — including deaths — linked to Amgen’s rare‑disease drug Tavneos (76 cases identified). The agency is urging closer monitoring and prompt discontinuation if liver damage is suspected; this poses regulatory, reputational and potential liability risks that could pressure the stock. US FDA warns of liver injury cases tied to Amgen’s rare disease drug FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths
• Negative Sentiment: Biosimilars competition: Teva won FDA approval for a Prolia biosimilar (Ponlimsi) and advanced other biosimilar filings — increased biosimilars activity raises competitive pressure in areas where Amgen has legacy biologics, potentially weighing on future sales. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AMGN. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Guggenheim raised their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research report on Tuesday, January 20th. Rothschild & Co Redburn increased their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Finally, Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.